Immix Biopharma (IMMX) Research & Development (2021 - 2026)
Immix Biopharma (IMMX) reported Research & Development of $6.0 million for Q1 2026, up 202.8% on a YoY basis from $2.0 million in Q1 2025, and up 4.43% sequentially from $5.7 million in Q4 2025.
Immix Biopharma (IMMX) Research & Development (2021 - 2026) Analysis & Trends
Immix Biopharma (IMMX) has 6 years of Research & Development data on file, last reported at $6.0 million in Q1 2026.
- For the quarter ending Q1 2026, Research & Development rose 202.8% year-over-year to $6.0 million; the trailing twelve-month figure through Mar 2026 stood at $20.3 million (up 102.25% YoY), and the FY2025 full-year result was $16.3 million, up 43.97% from the prior year.
- Research & Development improved to $6.0 million in Q1 2026, from $5.7 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $6.0 million in Q1 2026 to a low of $607751.0 in Q2 2022.
- A 5-year average of $2.7 million and a median of $2.2 million in 2024 frame the typical range for Research & Development.
- Across the five-year window, Research & Development surged 24397.17% in 2022 and sank 55.68% in 2024, its largest moves.
- Tracing IMMX's Research & Development over 5 years: stood at $2.3 million in 2022, then jumped by 37.05% to $3.1 million in 2023, then plunged by 55.68% to $1.4 million in 2024, then soared by 316.7% to $5.7 million in 2025, then grew by 4.43% to $6.0 million in 2026.
- Business Quant data shows IMMX's Research & Development at $6.0 million in Q1 2026, $5.7 million in Q4 2025, and $4.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -17.94 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 1.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 541.22 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 961.60 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 1.54 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | 15.66 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | -443.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 343.97 Mn |
| 10 | Immix Biopharma | 473.68 Mn | 473.68 Mn | - | 5.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.98 Mn |
| Dec 31, 2025 | 5.73 Mn |
| Sep 30, 2025 | 4.58 Mn |
| Jun 30, 2025 | 3.97 Mn |
| Mar 31, 2025 | 1.98 Mn |
| Dec 31, 2024 | 1.37 Mn |
| Sep 30, 2024 | 4.45 Mn |
| Jun 30, 2024 | 2.22 Mn |
| Mar 31, 2024 | 3.25 Mn |
| Dec 31, 2023 | 3.10 Mn |
| Sep 30, 2023 | 2.11 Mn |
| Jun 30, 2023 | 2.21 Mn |
| Mar 31, 2023 | 1.32 Mn |
| Dec 31, 2022 | 2.26 Mn |
| Sep 30, 2022 | 695,937.00 |
| Jun 30, 2022 | 607,751.00 |
| Mar 31, 2022 | 629,531.00 |
| Dec 31, 2021 | 9,236.00 |
| Sep 30, 2021 | 29,690.00 |
| Jun 30, 2021 | 62,761.00 |